[Skip to Content]
[Skip to Content Landing]
Editorial
November 12, 2019

Bempedoic Acid for Lowering LDL Cholesterol

Author Affiliations
  • 1Cardiology Division, Massachusetts General Hospital, Harvard Medical School, Boston
  • 2Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston
  • 3Program in Medical and Population Genetics, Broad Institute of Harvard and Massachusetts Institute of Technology (MIT), Cambridge
  • 4Cardiovascular Research Center and Center for Genomic Medicine, Massachusetts General Hospital, Boston
JAMA. 2019;322(18):1769-1771. doi:10.1001/jama.2019.16598

Since the report of the first expert panel of the National Cholesterol Education Program in 1988, effectively the first contemporary professional cholesterol guidelines in the United States, lowering of low-density lipoprotein cholesterol (LDL-C) levels has been a cornerstone of atherosclerotic cardiovascular disease (ASCVD) prevention. Consistent with classical and genetic epidemiologic studies implying a causal relationship between LDL-C and ASCVD, multiple randomized clinical trials have consistently observed proportional relationships between LDL-C lowering and ASCVD risk reduction from statins. More recently, these findings have extended to nonstatin LDL-C–lowering medicines, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9)–inhibiting monoclonal antibodies.1-3

×